TSHA FY2026 EPS Forecast Raised by Cantor Fitzgerald

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) – Analysts at Cantor Fitzgerald raised their FY2026 EPS estimates for Taysha Gene Therapies in a research report issued to clients and investors on Monday, November 24th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings of ($0.47) per share for the year, up from their previous forecast of ($0.48). Cantor Fitzgerald currently has a “Overweight” rating and a $13.00 price objective on the stock. The consensus estimate for Taysha Gene Therapies’ current full-year earnings is ($0.35) per share.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its earnings results on Tuesday, November 4th. The company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 67.26%.

TSHA has been the topic of a number of other research reports. Wall Street Zen lowered Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. JMP Securities set a $8.00 price objective on Taysha Gene Therapies in a research report on Wednesday, November 5th. Raymond James Financial assumed coverage on Taysha Gene Therapies in a report on Tuesday, October 21st. They set a “strong-buy” rating and a $13.00 target price for the company. Chardan Capital restated a “buy” rating and issued a $12.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $10.30.

Taysha Gene Therapies Trading Up 5.9%

Shares of TSHA stock opened at $4.86 on Wednesday. Taysha Gene Therapies has a 12-month low of $1.05 and a 12-month high of $5.51. The company has a market capitalization of $1.33 billion, a PE ratio of -14.73 and a beta of 1.00. The firm has a 50 day moving average price of $4.29 and a two-hundred day moving average price of $3.27. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23.

Hedge Funds Weigh In On Taysha Gene Therapies

Several hedge funds and other institutional investors have recently made changes to their positions in TSHA. Marex Group plc acquired a new stake in shares of Taysha Gene Therapies during the 2nd quarter worth approximately $29,000. E Fund Management Co. Ltd. acquired a new stake in shares of Taysha Gene Therapies in the 2nd quarter valued at $31,000. ST Germain D J Co. Inc. boosted its holdings in shares of Taysha Gene Therapies by 81.8% in the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock valued at $32,000 after purchasing an additional 4,333 shares in the last quarter. May Hill Capital LLC bought a new position in shares of Taysha Gene Therapies in the 2nd quarter valued at $37,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in shares of Taysha Gene Therapies during the 3rd quarter worth $40,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $3.23, for a total transaction of $646,000.00. Following the sale, the insider directly owned 1,006,439 shares in the company, valued at $3,250,797.97. This represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 3.78% of the stock is owned by corporate insiders.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.